Stock listing

Bioage Labs, Inc.

Selected listing: Y7G · DUS · EUR · DE

Bioage Labs, Inc. (Dusseldorf:Y7G), Health Technology. Latest release Sep 8, 2026: BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial…

Y7G:DUSEURDEUpdated August 31, 2026

Ticker: Dusseldorf:Y7G
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Dusseldorf
Currency: EUR

Latest news from Bioage Labs, Inc.

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

September 8, 2026

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 5, 2026

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

July 14, 2026

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

June 16, 2026

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026

All Bioage Labs, Inc. news →

Research Bioage Labs, Inc.

Bioage Labs, Inc. company profile

View the public company page for Bioage Labs, Inc. on 6ix.

Bioage Labs, Inc. news

Read company news and market updates connected to Bioage Labs, Inc..

Bioage Labs, Inc. investor events

Find investor webinars, events, and replay context for Bioage Labs, Inc..